Micro- and Nano-Delivery for BFS Skincare OEM/ODM

An active ingredient, its delivery system and its final packaging need to work together. For a skincare brand developing a single-dose serum, the useful question is whether that combination remains suitable through manufacture, storage and use.

At Steridose Labs, our BFS skincare OEM/ODM service connects formula development or transfer with filling, labelling and finished packaging. Our project review brings the candidate delivery system, formulation evidence and filling compatibility into one development brief before a production route is agreed.

What is micro- and nano-delivery in skincare?

Micro- and nano-delivery describe formulation approaches that use small droplets, particles or carrier structures to organise ingredients within a product. Depending on the system, the development objective may be to protect an ingredient, improve its dispersion or investigate a particular release profile. Each objective needs its own evidence.

A technology name alone does not tell a buyer the carrier composition, particle distribution, ingredient loading or performance of the finished serum. Those details belong to the actual formulation specification.

For a brand, this turns a broad technology discussion into three practical questions: what is being carried, how is it characterised, and what happens to it in the final product?

How does this relate to BFS ampoules?

Micro- or nano-delivery concerns the formulation inside the pack. Blow-fill-seal, or BFS, concerns forming the container, filling it and sealing it. A delivery system is not created simply by filling a formula into a BFS ampoule.

1. Formulation: agree the active, carrier and base for the intended cosmetic use, then define the formula direction and evaluation plan.
2. Filling and container: assess the bulk formula against the proposed process, material, fill volume and opening design, then define the filling route and packaging specification.
3. Finished product: agree what must remain acceptable after filling, storage and intended use, including the tests, acceptance criteria and approved presentation.

A promising laboratory dispersion is a starting point. The filled ampoule needs its own evaluation because the product being sold includes both the formula and the package.

Explore our BFS skincare ampoules.

What should particle data actually show?

Ask for the sample identity, measurement method, preparation conditions and reporting basis alongside the result. A raw carrier, a diluted test sample and the complete serum are different samples; their numbers should not be presented as interchangeable.

For dynamic light scattering, or DLS, the polydispersity index describes an aspect of distribution breadth calculated from the measurement. It is not a skin-absorption score. Malvern Panalytical explains how the PDI and z-average are derived and why sample quality matters. Read its DLS size-quality technical note.

A particle-size measurement cannot, on its own, establish encapsulation efficiency, ingredient retention, a release profile or a cosmetic benefit. Request the evidence that answers the particular product claim, rather than asking one graph to support them all.

From a delivery concept to a finished serum

Our development review follows four product decisions.

Choose the product objective. Define the cosmetic use, target market, active ingredient and desired texture. Decide whether a delivery system solves a specific formulation problem and what comparison would demonstrate that.

Characterise the candidate formula. Identify the carrier and base, agree appropriate particle measurements, and determine which stability and active-content checks are relevant. Compare like-for-like samples using a defined method.

Review filling and pack compatibility. Assess the proposed manufacturing conditions, bulk handling, container material, target fill, seal and dispensing experience. Agree which characteristics should be compared before and after filling.

Evaluate the finished product. Set acceptance criteria for the selected formula and pack, including relevant stability, microbiological quality, safety and claim support. A proposal for a water-like serum does not establish suitability for a cream or a sunscreen formulation.

Your development brief should identify the chosen formula, the next sample or trial to evaluate, the required records and who approves each stage. This keeps the path from formulation work to a filled product clear.

What evidence supports a nano skincare project?

FDA guidance recommends considering material characteristics, particle distribution, aggregation in the final product and exposure when assessing cosmetics using nanomaterials. This is why safety review needs to follow the actual ingredient and intended use, rather than rely on the word “nano.” FDA safety guidance for nanomaterials in cosmetic products.

For projects intended for European markets, the SCCS guidance provides a further reference for nanomaterial characterisation and safety assessment. Whether a material falls within the applicable definition and requirements needs a product-specific review. SCCS guidance on the safety assessment of nanomaterials in cosmetics.

The practical outcome is a connected evidence set: the identity of the material, its behaviour in the formula, relevant finished-pack results and support for the claims the brand intends to make.

Review quality and documentation.

Common questions from skincare brands

Does a smaller particle size mean better skin performance?

Size alone does not establish performance. Composition, the finished formula, intended use and the relevant test results determine what can be said about a product. A distribution graph should not be described as proof of deep penetration or targeted delivery.

Can an existing encapsulated serum be transferred into BFS?

It can be submitted for a formula and packaging review. The proposed carrier, complete formulation, bulk-handling conditions, selected container and filling process need to be assessed before suitability is confirmed.

Does single-dose packaging remove the need for a preservation review?

No. Formula composition, manufacturing conditions, microbiological quality, packaging and intended use still need to be considered together. The presence of a nano-delivery system or a single-dose pack does not by itself establish a particular preservation claim.

What is the starting quantity for a BFS skincare project?

Our BFS route starts at 10,000 filled ampoules per formula. Confirm the selected formula, capacity, packaging components and project scope before production. This quantity does not describe the minimum order for every other skincare format.

What should we send to begin?

Share the product concept or existing formula status, intended cosmetic use, target market, preferred fill volume and estimated quantity. If a delivery system is already selected, include its technical description and the available test summary. Proprietary formulation details can follow an NDA discussion.

Discuss your formula and BFS packaging brief

Start with the product you want to make and the evidence you already have. Steridose Labs can help scope the formula-development or transfer work, sample evaluation, BFS filling and finished-pack requirements for your project.

Discuss your skincare OEM/ODM project.